94 related articles for article (PubMed ID: 31456585)
1. Factors associated with recurrent leptomeningeal metastases in patients with EGFR-mutated non-small-cell lung cancer.
Watanabe H; Okauchi S; Miyazaki K; Satoh H; Hizawa N
Pol Arch Intern Med; 2019 Nov; 129(11):836-838. PubMed ID: 31456585
[No Abstract] [Full Text] [Related]
2. Brief Report: EGFR L833V/H835L Duplex-Mutated NSCLC With Leptomeningeal Carcinomatosis Responsive to Osimertinib.
Smith JT; Puri S; Akerley W
Clin Lung Cancer; 2023 Jun; 24(4):360-361. PubMed ID: 36935243
[No Abstract] [Full Text] [Related]
3. Focal Leptomeningeal Disease with Perivascular Invasion in
Dasgupta A; Moraes FY; Rawal S; Diamandis P; Shultz DB
AJNR Am J Neuroradiol; 2020 Aug; 41(8):1430-1433. PubMed ID: 32616581
[TBL] [Abstract][Full Text] [Related]
4. EGFR exon 19 deletion mutations and systemic/central nervous system miliary metastasis: clinical correlations and response to therapy.
Poonia S; Berge EM; Aisner DL; Damek D; Doebele RC
Clin Lung Cancer; 2014 Sep; 15(5):387-9. PubMed ID: 24894944
[No Abstract] [Full Text] [Related]
5. Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis.
Yan W; Liu Y; Li J; Han A; Kong L; Yu J; Zhu H
Radiat Oncol; 2019 Sep; 14(1):168. PubMed ID: 31521171
[TBL] [Abstract][Full Text] [Related]
6. Epidermal Growth Factor Receptor Mutation Detection in Cerebrospinal Fluid of Lung Adenocarcinoma Patients with Leptomeningeal Metastasis.
Huang R; Ge M; Zhou X; Ji X; Liao L; Liang X; Zhan Q
Cancer Biother Radiopharm; 2019 Mar; 34(2):128-133. PubMed ID: 30452286
[TBL] [Abstract][Full Text] [Related]
7. Circulating epithelial tumor cell analysis in CSF in patients with leptomeningeal metastases.
van Bussel MTJ; Pluim D; Milojkovic Kerklaan B; Bol M; Sikorska K; Linders DTC; van den Broek D; Beijnen JH; Schellens JHM; Brandsma D
Neurology; 2020 Feb; 94(5):e521-e528. PubMed ID: 31907288
[TBL] [Abstract][Full Text] [Related]
8. Clinical Efficacy of Afatinib Treatment for a Patient with Leptomeningeal Carcinomatosis.
Kawaguchi Y; Hanaoka J; Hayashi H; Mizusaki N; Iihara H; Itoh Y; Sugiyama T
Chemotherapy; 2017; 62(3):147-150. PubMed ID: 28030859
[TBL] [Abstract][Full Text] [Related]
9. Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer.
Wu YL; Zhao Q; Deng L; Zhang Y; Zhou XJ; Li YY; Yu M; Zhou L; Zou BW; Lu Y; Liu YM
Lung Cancer; 2019 Jan; 127():1-5. PubMed ID: 30642536
[TBL] [Abstract][Full Text] [Related]
10. Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma.
Longo L; Mengoli MC; Bertolini F; Bettelli S; Manfredini S; Rossi G
Lung Cancer; 2017 Jan; 103():24-26. PubMed ID: 28024692
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib treatment of meningeal carcinomatosis in lung cancer: more is better.
Cessot A; Blanchet B; Goldwasser F
Ann Oncol; 2014 Oct; 25(10):2093-2094. PubMed ID: 25057169
[No Abstract] [Full Text] [Related]
12. Long-term outcome after multidisciplinary approach for leptomeningeal carcinomatosis in a non-small cell lung cancer patient with poor performance status.
Nagano T; Kotani Y; Kobayashi K; Hatakeyama Y; Hori S; Kasai D; Funada Y; Nishimura H; Kondoh T; Nishimura Y
Intern Med; 2011; 50(24):3019-22. PubMed ID: 22185996
[TBL] [Abstract][Full Text] [Related]
13. Unusual progressive neurological syndrome in epidermal growth factor receptor-mutated lung adenocarcinoma, diagnosed at autopsy as invasive meningeal carcinomatosis.
Mezquita-Pérez L; Pian H; García N
Arch Bronconeumol; 2016 Nov; 52(11):571-572. PubMed ID: 27156984
[No Abstract] [Full Text] [Related]
14. Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study.
Tamiya A; Tamiya M; Nishihara T; Shiroyama T; Nakao K; Tsuji T; Takeuchi N; Isa SI; Omachi N; Okamoto N; Suzuki H; Okishio K; Iwazaki A; Imai K; Hirashima T; Atagi S
Anticancer Res; 2017 Aug; 37(8):4177-4182. PubMed ID: 28739703
[TBL] [Abstract][Full Text] [Related]
15. High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases--one with a remarkable thoracic response as well.
Kuiper JL; Smit EF
Lung Cancer; 2013 Apr; 80(1):102-5. PubMed ID: 23375403
[TBL] [Abstract][Full Text] [Related]
16. Leptomeningeal recurrence after long-term alectinib therapy for non-small cell lung cancer harboring an EML4-ALK fusion protein.
Kawamura T; Murakami H; Kobayashi H; Nakashima K; Omori S; Wakuda K; Ono A; Kenmotsu H; Naito T; Endo M; Takahashi T
Invest New Drugs; 2019 Feb; 37(1):184-187. PubMed ID: 29971546
[TBL] [Abstract][Full Text] [Related]
17. Post-recurrence survival analysis of stage I non-small-cell lung cancer.
Lee K; Kim HR; Kim DK; Kim YH; Park SI; Choi SH; Han J
Asian Cardiovasc Thorac Ann; 2017 Nov; 25(9):623-629. PubMed ID: 29058973
[TBL] [Abstract][Full Text] [Related]
18. Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer.
Kawamura T; Kenmotsu H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Omae K; Mori K; Tanigawara Y; Nakajima T; Ohde Y; Endo M; Takahashi T
Clin Lung Cancer; 2018 Mar; 19(2):e247-e252. PubMed ID: 28866043
[TBL] [Abstract][Full Text] [Related]
19. Radiographic appearance of leptomeningeal disease in patients with EGFR-mutated non-small-cell lung carcinoma treated with tyrosine kinase inhibitors: a case series.
Sener U; Matin N; Yu H; Lin A; Yang TJ; Malani R
CNS Oncol; 2019 Dec; 8(4):CNS42. PubMed ID: 31777268
[TBL] [Abstract][Full Text] [Related]
20. Thoracoscopic rebiopsy to detect the T790M mutation after postoperative recurrence.
Hamaji M; Motoyama H; Menju T; Chen-Yoshikawa TF; Sonobe M; Kim YH; Date H
Interact Cardiovasc Thorac Surg; 2018 Oct; 27(4):606-608. PubMed ID: 29618075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
